RT @doctorRBC: How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/func
Tweet Content
How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%?
@RheumNow #EULAR2022 ABST#OP0025
Show on Archive Page
On
Display in Search Results
On
PDQ
Off